Cargando…

Antimicrobial Resistance Profile of Different Clinical Isolates against Third-Generation Cephalosporins

BACKGROUND: Drug resistant microorganisms lead to an increase in morbidity and mortality as they boost the risk of inappropriate therapy. Hence, data on antimicrobial resistance help define the best possible treatment for individual patients. Therefore, this study aimed to screen the antimicrobial r...

Descripción completa

Detalles Bibliográficos
Autores principales: Gashe, Fanta, Mulisa, Eshetu, Mekonnen, Mekidim, Zeleke, Gemechu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151245/
https://www.ncbi.nlm.nih.gov/pubmed/30271652
http://dx.doi.org/10.1155/2018/5070742
_version_ 1783357124366041088
author Gashe, Fanta
Mulisa, Eshetu
Mekonnen, Mekidim
Zeleke, Gemechu
author_facet Gashe, Fanta
Mulisa, Eshetu
Mekonnen, Mekidim
Zeleke, Gemechu
author_sort Gashe, Fanta
collection PubMed
description BACKGROUND: Drug resistant microorganisms lead to an increase in morbidity and mortality as they boost the risk of inappropriate therapy. Hence, data on antimicrobial resistance help define the best possible treatment for individual patients. Therefore, this study aimed to screen the antimicrobial resistant profile of 3rd generation cephalosporin drugs in Jimma University Specialized Teaching Hospital. METHODS: A hospital based prospective cross-sectional study was conducted in Jimma University Specialized Hospital (JUSH) from April to August 2016. The clinical samples such as wound swab, urine, sputum, and stool were collected from hospitalized patients. Then, bacterial species were isolated and identified as per the standard microbiological methods. Antimicrobial susceptibility tests were carried out using various antimicrobial discs by Kirby–Bauer disc diffusion method. RESULTS: Totally, 248 bacterial isolates were obtained from 154 (62.1%) male and 94 (37.9%) female patients. Escherichia coli (25.4%) and Staphylococcus aureus (19.0 %) were the predominant organisms isolated from specimens. About 140 (56.5%) and 149 (60.1%) of the total bacterial isolates were found to be resistant to ceftriaxone and ceftazidime, respectively. The majority of Escherichia coli isolates 46 (73%) were resistant to ceftriaxone and 41 (65%) of them were resistant to ceftazidime. Staphylococcus aureus, which accounted 19% of the total bacterial isolates, showed 23.4% and 34% resistance to ceftriaxone and ceftazidime, respectively. Among the bacterial strains revealing resistant to ceftriazone and ceftazidime, about 109 (44%) and 108 (43.5%) of them were resistant to two, three, or four other drugs, respectively. CONCLUSION: Bacterial resistance towards third-generation cephalosporin (ceftriaxone and ceftazidime) is escalating as more than half of the isolated strains demonstrated resistance to these drugs. Moreover, these strains also revealed multidrug resistance mainly against clinically used drugs which could render therapy unsuccessful. Therefore, in clinical use appropriate medications should be selected based on the data obtained from antimicrobial susceptibility tests.
format Online
Article
Text
id pubmed-6151245
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-61512452018-09-30 Antimicrobial Resistance Profile of Different Clinical Isolates against Third-Generation Cephalosporins Gashe, Fanta Mulisa, Eshetu Mekonnen, Mekidim Zeleke, Gemechu J Pharm (Cairo) Research Article BACKGROUND: Drug resistant microorganisms lead to an increase in morbidity and mortality as they boost the risk of inappropriate therapy. Hence, data on antimicrobial resistance help define the best possible treatment for individual patients. Therefore, this study aimed to screen the antimicrobial resistant profile of 3rd generation cephalosporin drugs in Jimma University Specialized Teaching Hospital. METHODS: A hospital based prospective cross-sectional study was conducted in Jimma University Specialized Hospital (JUSH) from April to August 2016. The clinical samples such as wound swab, urine, sputum, and stool were collected from hospitalized patients. Then, bacterial species were isolated and identified as per the standard microbiological methods. Antimicrobial susceptibility tests were carried out using various antimicrobial discs by Kirby–Bauer disc diffusion method. RESULTS: Totally, 248 bacterial isolates were obtained from 154 (62.1%) male and 94 (37.9%) female patients. Escherichia coli (25.4%) and Staphylococcus aureus (19.0 %) were the predominant organisms isolated from specimens. About 140 (56.5%) and 149 (60.1%) of the total bacterial isolates were found to be resistant to ceftriaxone and ceftazidime, respectively. The majority of Escherichia coli isolates 46 (73%) were resistant to ceftriaxone and 41 (65%) of them were resistant to ceftazidime. Staphylococcus aureus, which accounted 19% of the total bacterial isolates, showed 23.4% and 34% resistance to ceftriaxone and ceftazidime, respectively. Among the bacterial strains revealing resistant to ceftriazone and ceftazidime, about 109 (44%) and 108 (43.5%) of them were resistant to two, three, or four other drugs, respectively. CONCLUSION: Bacterial resistance towards third-generation cephalosporin (ceftriaxone and ceftazidime) is escalating as more than half of the isolated strains demonstrated resistance to these drugs. Moreover, these strains also revealed multidrug resistance mainly against clinically used drugs which could render therapy unsuccessful. Therefore, in clinical use appropriate medications should be selected based on the data obtained from antimicrobial susceptibility tests. Hindawi 2018-09-09 /pmc/articles/PMC6151245/ /pubmed/30271652 http://dx.doi.org/10.1155/2018/5070742 Text en Copyright © 2018 Fanta Gashe et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Gashe, Fanta
Mulisa, Eshetu
Mekonnen, Mekidim
Zeleke, Gemechu
Antimicrobial Resistance Profile of Different Clinical Isolates against Third-Generation Cephalosporins
title Antimicrobial Resistance Profile of Different Clinical Isolates against Third-Generation Cephalosporins
title_full Antimicrobial Resistance Profile of Different Clinical Isolates against Third-Generation Cephalosporins
title_fullStr Antimicrobial Resistance Profile of Different Clinical Isolates against Third-Generation Cephalosporins
title_full_unstemmed Antimicrobial Resistance Profile of Different Clinical Isolates against Third-Generation Cephalosporins
title_short Antimicrobial Resistance Profile of Different Clinical Isolates against Third-Generation Cephalosporins
title_sort antimicrobial resistance profile of different clinical isolates against third-generation cephalosporins
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151245/
https://www.ncbi.nlm.nih.gov/pubmed/30271652
http://dx.doi.org/10.1155/2018/5070742
work_keys_str_mv AT gashefanta antimicrobialresistanceprofileofdifferentclinicalisolatesagainstthirdgenerationcephalosporins
AT mulisaeshetu antimicrobialresistanceprofileofdifferentclinicalisolatesagainstthirdgenerationcephalosporins
AT mekonnenmekidim antimicrobialresistanceprofileofdifferentclinicalisolatesagainstthirdgenerationcephalosporins
AT zelekegemechu antimicrobialresistanceprofileofdifferentclinicalisolatesagainstthirdgenerationcephalosporins